CRESCENT BIOPHARMA, INC. Research and Development Expense
CRESCENT BIOPHARMA, INC. (CBIO) reported Research and Development Expense of $19.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $19.39M, a 60.51% increase year-over-year.
- CRESCENT BIOPHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $17.90M, a 68.47% increase year-over-year.
- CRESCENT BIOPHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $95.03M, a 577.12% increase year-over-year.
- CRESCENT BIOPHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $20.35M, a 1086.17% increase year-over-year.
- CRESCENT BIOPHARMA, INC. research and development expense for fiscal 2025 was $138.09M, a 868.36% increase from fiscal 2024.
- CRESCENT BIOPHARMA, INC. research and development expense for fiscal 2024 was $14.26M, a 28.96% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. research and development expense for fiscal 2023 was $20.07M, a 29.30% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. research and development expense for fiscal 2022 was $28.39M, a 40.22% decline from fiscal 2021.
| Period end | Research and Development Expense 0 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 130 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.39M 10-Q · filed 2026-07-30 | $37.29M 10-Q · filed 2026-07-30 | $132.32M derived: sum of 3 quarters · filed 2026-07-30 | $152.67M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $17.90M 10-Q · filed 2026-04-29 | $112.93M derived: sum of 2 quarters · filed 2026-04-29 | $133.28M derived: sum of 3 quarters · filed 2026-04-29 | $145.36M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | $95.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.37M derived: sum of 2 quarters · filed 2026-02-26 | $127.45M derived: sum of 3 quarters · filed 2026-07-30 | $138.09M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $20.35M 10-Q · filed 2025-11-06 | $32.43M derived: sum of 2 quarters · filed 2026-07-30 | $43.06M 10-Q · filed 2025-11-06 | $57.09M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $12.08M 10-Q · filed 2026-07-30 | $22.71M 10-Q · filed 2026-07-30 | $36.74M derived: sum of 3 quarters · filed 2026-07-30 | $38.46M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $10.63M 10-Q · filed 2026-04-29 | $14.78K 10-Q · filed 2025-05-14 | $24.66M derived: sum of 2 quarters · filed 2026-04-29 | $26.38M derived: sum of 3 quarters · filed 2026-04-29 | $32.66M derived: sum of 4 quarters · filed 2026-04-29 | ||
| 2024-12-31 | $14.03M 10-K · filed 2026-02-26 | $15.75M derived: sum of 2 quarters · filed 2026-02-26 | $22.04M derived: sum of 3 quarters · filed 2026-02-26 | $14.26M 10-K · filed 2025-02-13 | |||
| 2024-09-30 | $2.47M 10-Q · filed 2025-11-06 | $1.72M 10-Q · filed 2024-11-13 | $8.00M derived: sum of 2 quarters · filed 2024-11-13 | $14.03M 10-Q · filed 2024-11-13 | $19.31M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-06-30 | $6.29M 10-Q · filed 2024-08-08 | $12.31M 10-Q · filed 2024-08-08 | $17.60M derived: sum of 3 quarters · filed 2025-05-14 | $22.89M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2024-03-31 | $6.03M 10-Q · filed 2025-05-14 | $11.31M derived: sum of 2 quarters · filed 2025-05-14 | $16.61M derived: sum of 3 quarters · filed 2025-05-14 | $20.68M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $10.58M derived: sum of 2 quarters · filed 2025-02-13 | $14.65M derived: sum of 3 quarters · filed 2025-02-13 | $20.07M 10-K · filed 2025-02-13 | |||
| 2023-09-30 | $5.29M 10-Q · filed 2024-11-13 | $9.36M derived: sum of 2 quarters · filed 2024-11-13 | $14.78M 10-Q · filed 2024-11-13 | $20.67M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $4.07M 10-Q · filed 2024-08-08 | $9.49M 10-Q · filed 2024-08-08 | $15.38M derived: sum of 3 quarters · filed 2024-08-08 | $20.31M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $5.42M 10-Q · filed 2024-05-09 | $11.31M derived: sum of 2 quarters · filed 2024-05-09 | $16.23M derived: sum of 3 quarters · filed 2024-05-09 | $24.21M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $10.81M derived: sum of 2 quarters · filed 2024-03-27 | $18.79M derived: sum of 3 quarters · filed 2024-03-27 | $28.39M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $4.92M 10-Q · filed 2023-11-03 | $12.90M derived: sum of 2 quarters · filed 2023-11-03 | $22.50M 10-Q · filed 2023-11-03 | $35.40M derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2022-06-30 | $7.97M 10-Q · filed 2023-08-02 | $17.58M 10-Q · filed 2023-08-02 | $30.47M derived: sum of 3 quarters · filed 2024-03-27 | $43.75M derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2022-03-31 | $9.60M 10-Q · filed 2023-05-03 | $22.50M derived: sum of 2 quarters · filed 2024-03-27 | $35.78M derived: sum of 3 quarters · filed 2024-03-27 | $45.95M derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2021-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $26.18M derived: sum of 2 quarters · filed 2024-03-27 | $36.34M derived: sum of 3 quarters · filed 2024-03-27 | $47.49M 10-K · filed 2024-03-27 | |||
| 2021-09-30 | $13.28M 10-Q · filed 2022-11-09 | $23.45M derived: sum of 2 quarters · filed 2022-11-09 | $34.60M 10-Q · filed 2022-11-09 | $46.32M derived: sum of 4 quarters · filed 2023-03-29 | |||
| 2021-06-30 | $10.17M 10-Q · filed 2022-08-03 | $21.31M 10-Q · filed 2022-08-03 | $33.03M derived: sum of 3 quarters · filed 2023-03-29 | $43.70M derived: sum of 4 quarters · filed 2023-03-29 | |||
| 2021-03-31 | $11.15M 10-Q · filed 2022-04-28 | $22.87M derived: sum of 2 quarters · filed 2023-03-29 | $33.54M derived: sum of 3 quarters · filed 2023-03-29 | $43.41M derived: sum of 4 quarters · filed 2023-03-29 | |||
| 2020-12-31 | $11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $22.39M derived: sum of 2 quarters · filed 2023-03-29 | $32.26M derived: sum of 3 quarters · filed 2023-03-29 | $44.93M 10-K · filed 2023-03-29 | |||
| 2020-09-30 | $10.67M 10-Q · filed 2021-11-02 | $20.54M derived: sum of 2 quarters · filed 2021-11-02 | $33.21M 10-Q · filed 2021-11-02 | $44.68M derived: sum of 4 quarters · filed 2022-03-03 | |||
| 2020-06-30 | $9.87M 10-Q · filed 2021-08-05 | $22.54M 10-Q · filed 2021-08-05 | $34.01M derived: sum of 3 quarters · filed 2022-03-03 | $44.73M derived: sum of 4 quarters · filed 2022-03-03 | |||
| 2020-03-31 | $12.67M 10-Q · filed 2021-05-03 | $24.14M derived: sum of 2 quarters · filed 2022-03-03 | $34.86M derived: sum of 3 quarters · filed 2022-03-03 | $47.92M derived: sum of 4 quarters · filed 2022-03-03 | |||
| 2019-12-31 | $11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $22.19M derived: sum of 2 quarters · filed 2022-03-03 | $35.26M derived: sum of 3 quarters · filed 2022-03-03 | $47.03M 10-K · filed 2022-03-03 | |||
| 2019-09-30 | $10.72M 10-Q · filed 2020-11-06 | $23.79M derived: sum of 2 quarters · filed 2020-11-06 | $35.56M 10-Q · filed 2020-11-06 | $47.60M derived: sum of 4 quarters · filed 2021-03-02 | |||
| 2019-06-30 | $13.07M 10-Q · filed 2020-07-31 | $24.84M 10-Q · filed 2020-07-31 | $36.88M derived: sum of 3 quarters · filed 2021-03-02 | $46.61M derived: sum of 4 quarters · filed 2021-03-02 | |||
| 2019-03-31 | $11.77M 10-Q · filed 2020-05-01 | $23.81M derived: sum of 2 quarters · filed 2021-03-02 | $33.54M derived: sum of 3 quarters · filed 2021-03-02 | $42.84M derived: sum of 4 quarters · filed 2021-03-02 | |||
| 2018-12-31 | $12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $21.77M derived: sum of 2 quarters · filed 2021-03-02 | $31.07M derived: sum of 3 quarters · filed 2021-03-02 | $40.09M 10-K · filed 2021-03-02 | |||
| 2018-09-30 | $9.73M 10-Q · filed 2019-11-07 | $19.03M derived: sum of 2 quarters · filed 2019-11-07 | $28.05M 10-Q · filed 2019-11-07 | $35.05M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | $9.30M 10-Q · filed 2018-08-09 | $18.32M 10-Q · filed 2019-08-01 | $25.32M derived: sum of 3 quarters · filed 2020-02-28 | $31.10M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-03-31 | $9.30M 10-Q · filed 2019-08-01 | $9.02M 10-Q · filed 2018-05-03 | $16.02M derived: sum of 2 quarters · filed 2020-02-28 | $21.80M derived: sum of 3 quarters · filed 2020-02-28 | $27.52M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2017-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $12.50M derived: sum of 2 quarters · filed 2020-02-28 | $18.22M derived: sum of 3 quarters · filed 2020-02-28 | $24.10M 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $5.78M 10-Q · filed 2018-11-02 | $11.50M derived: sum of 2 quarters · filed 2018-11-02 | $17.38M 10-Q · filed 2018-11-02 | $23.44M derived: sum of 4 quarters · filed 2019-03-06 | |||
| 2017-06-30 | $5.72M 10-Q · filed 2018-08-09 | $11.60M 10-Q · filed 2018-08-09 | $17.66M derived: sum of 3 quarters · filed 2019-03-06 | $23.58M derived: sum of 4 quarters · filed 2019-03-06 | |||
| 2017-03-31 | $5.88M 10-Q · filed 2018-05-03 | $11.94M derived: sum of 2 quarters · filed 2019-03-06 | $17.86M derived: sum of 3 quarters · filed 2019-03-06 | $23.64M derived: sum of 4 quarters · filed 2019-03-06 | |||
| 2016-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $11.98M derived: sum of 2 quarters · filed 2019-03-06 | $17.76M derived: sum of 3 quarters · filed 2019-03-06 | $23.28M 10-K · filed 2019-03-06 | |||
| 2016-09-30 | $5.92M 10-Q · filed 2017-11-08 | $11.70M derived: sum of 2 quarters · filed 2017-11-08 | $17.22M 10-Q · filed 2017-11-08 | $24.18M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2016-06-30 | $5.78M 10-Q · filed 2017-08-03 | $11.30M 10-Q · filed 2017-08-03 | $18.26M derived: sum of 3 quarters · filed 2018-03-06 | $23.30M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2016-03-31 | $5.52M 10-Q · filed 2017-05-08 | $12.48M derived: sum of 2 quarters · filed 2018-03-06 | $17.52M derived: sum of 3 quarters · filed 2018-03-06 | $25.36M derived: sum of 4 quarters · filed 2018-03-06 | |||
| 2015-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $12.00M derived: sum of 2 quarters · filed 2018-03-06 | $19.84M derived: sum of 3 quarters · filed 2018-03-06 | $25.05M 10-K · filed 2018-03-06 | |||
| 2015-09-30 | $5.04M 10-Q · filed 2016-11-04 | $12.88M derived: sum of 2 quarters · filed 2016-11-04 | $18.09M 10-Q · filed 2016-11-04 | $23.37M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $7.84M 10-Q · filed 2016-08-04 | $13.05M 10-Q · filed 2016-08-04 | $18.33M derived: sum of 3 quarters · filed 2017-03-01 | $23.38M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $5.21M 10-Q · filed 2016-05-04 | $10.49M derived: sum of 2 quarters · filed 2017-03-01 | $15.54M derived: sum of 3 quarters · filed 2017-03-01 | $20.90M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $10.33M derived: sum of 2 quarters · filed 2017-03-01 | $15.69M derived: sum of 3 quarters · filed 2017-03-01 | $19.57M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $5.05M 10-Q · filed 2015-11-12 | $10.41M derived: sum of 2 quarters · filed 2015-11-12 | $14.29M 10-Q · filed 2015-11-12 | $17.41M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $5.36M 10-Q · filed 2015-08-06 | $9.24M 10-Q · filed 2015-08-06 | $12.36M derived: sum of 3 quarters · filed 2016-02-29 | $15.31M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $3.88M 10-Q · filed 2015-05-05 | $7.00M derived: sum of 2 quarters · filed 2016-02-29 | $9.96M derived: sum of 3 quarters · filed 2016-02-29 | $12.84M derived: sum of 4 quarters · filed 2016-02-29 | $74.68M 10-Q · filed 2014-05-09 | ||
| 2013-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $6.07M derived: sum of 2 quarters · filed 2016-02-29 | $8.96M derived: sum of 3 quarters · filed 2016-02-29 | $11.70M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $2.95M 10-Q · filed 2014-10-31 | $5.84M derived: sum of 2 quarters · filed 2014-10-31 | $8.58M 10-Q · filed 2014-10-31 | ||||
| 2013-06-30 | $2.88M 10-Q · filed 2014-07-31 | $5.63M 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | $2.74M 10-Q · filed 2014-05-09 | ||||||
| 2012-12-31 | $9.44M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |